Potential length of stay reductions from emergency department use of a point-of-care high-sensitivity cardiac troponin assay: Pilot findings from Australia's first cardiac emergency department

急诊科使用床旁高敏心肌肌钙蛋白检测可能缩短住院时间:澳大利亚首家心脏急诊科的试点研究结果

阅读:1

Abstract

OBJECTIVE: To compare actual ED length of stay (LOS) using laboratory-based high-sensitivity cardiac troponin I (hs-cTnI) testing with the potential LOS that could result from using point-of-care (POC) hs-cTnI tests. METHODS: Baseline hs-cTnI tests were performed on the same blood sample in the laboratory (Access hsTnI assay) and in the ED (Atellica VTLi POC assay). Actual and potential LOS were compared for patients who were discharged after having a baseline laboratory hs-cTnI test only. Total LOS incorporated time from arrival to blood sample collection, blood sampling to result availability and result availability to discharge. For potential LOS, the blood sampling to result availability time with POC use was fixed at 10 min (2-min preparation and 8-min test-processing). The laboratory blood sampling to result availability time was from blood sample collection to result uploading on the pathology computer system. For the study, it was assumed that this was the only LOS component that would differ with POC use. Invalid POC result rates were monitored. RESULTS: For 152 patients discharged after having a single baseline laboratory hs-cTnI test, the median actual LOS was 195 (interquartile range [IQR]: 152-319) min, which included a median laboratory blood-sampling-to-result-availability time of 48 (IQR: 41-59) min. The potential LOS from POC use was 157 (IQR: 103-282) min, which included the fixed 10-min blood-sampling-to-result-availability time. The mean actual-potential LOS difference was 43 (95% confidence interval [CI]: 40-46) min. The POC invalid result rate was 11%. CONCLUSION: The Atellica VTLi could deliver a mean ED LOS reduction of 43-min per patient for those discharged after a single baseline hs-cTnI test. Use in actual practice and the invalid result rate require further evaluation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。